Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages E521-E533

  Lenfert, Eva ^a,b   Maenz, Claudia ^a,b   Heinlein, Christina ^b   Jannasch, Katharina ^c   Schumacher, Udo ^a   Pantel, Klaus ^a   Tolstonog, Genrich V ^a,b,d   Deppert, Wolfgang ^a,b   Wegwitz, Florian ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Breast cancer; EMT; Metastasis; Mutp53; WAP T

Indexed keywords

PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPIC PLASTICITY; TRANSGENIC MOUSE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; ANIMAL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; HUMAN; METASTASIS; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MUTATION; NEOPLASM METASTASIS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922176430     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29186     Document Type: Article

References (56)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
3. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
4. Deppert W. Mutant p53 Oncogene. Oncogene 2007;26:2141-254.
5. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011;223: 116-26.
6. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012;33:2007-17.
7. Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med 2012;12:96-110.
8. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
9. Joshi H, Nord SH, Frigessi A, et al. Overrepresentation of transcription factor families in the gene-sets underlying breast cancer subtypes. BMC Genomics 2012;13:199.
10. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
11. Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007;4:e90.
12. Schulze-Garg C, Lohler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000;19:1028-37.
13. Heinlein C, Krepulat F, Lohler J, et al. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 2008;122:1701-9.
14. Wegwitz F, Kluth MA, Manz C, et al. Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. PLoS One 2010;5:e12103.
15. Jannasch K, Dullin C, Heinlein C, et al. Detection of different tumor growth kinetics in single transgenic mice with oncogene-induced mammary carcinomas by flat-panel volume computed tomography. Int J Cancer 2009;125:62-70.
16. Otto B, Gruner K, Heinlein C, et al. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression. Int J Cancer 2013;132:1300-10.
17. Otto B, Streichert T, Wegwitz F, et al. Transcription factors link mouse WAP-T mammary tumors with human breast cancer. Int J Cancer 2013;132:1311-22.
18. Pipas JM. SV40: cell transformation and tumorigenesis. Virology 2009;384:294-303.
19. Hirner H, Gunes C, Bischof J, et al. Impaired CK1 delta activity attenuates SV40-induced cellular transformation in vitro and mouse mammary carcinogenesis in vivo. PLoS One 2012;7:e29709.
20. Krepulat F, Lohler J, Heinlein C, et al. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene 2005;24:4645-59.
21. Li B, Murphy KL, Laucirica R, et al. A transgenic mouse model for mammary carcinogenesis. Oncogene 1998;16:997-1007.
22. Mollard S, Mousseau Y, Baaj Y, et al. How can grafted breast cancer models be optimized? Cancer Biol Ther 2011;12:855-64.
23. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
24. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-55.
25. Khromova NV, Kopnin PB, Stepanova EV, et al. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 2009;276:143-51.
26. Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial-mesenchymal transition. J Cell Biol 2012;197:421-37.
27. Taneyhill L, Pennica D. Identification of Wnt responsive genes using a murine mammary epithelial cell line model system. BMC Dev Biol 2004;4:6.
28. Jordan NV, Prat A, Abell AN, et al. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol Cell Biol 2013;33:3011-25.
29. Wu Q, Hou X, Xia J, et al. Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev 2013;39:640-6.
30. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 2012;139:3471-86.
31. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
32. Bianchi A, Gervasi ME, Bakin A. Role of beta5-integrin in epithelial-mesenchymal transition in response to TGF-beta. Cell Cycle 2010;9:1647-59.
33. Tiezzi DG, Fernandez SV, Russo J. Epithelial mesenchymal transition during the neoplastic transformation of human breast epithelial cells by estrogen. Int J Oncol 2007;31:823-7.
34. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 2012;5:261-73.
35. Gerstel D, Wegwitz F, Jannasch K, et al. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene 2011;30:4275-88.
36. Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology 2012;1:717-25.
37. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 2012;31:277-83.
38. Bonnomet A, Syne L, Brysse A, et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2012;31:3741-53.
39. Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009;137:87-98.
40. Roger L, Jullien L, Gire V, Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 2010;123:1295-305.
41. Termen S, Tan EJ, Heldin CH, Moustakas A. p53 regulates epithelial-mesenchymal transition induced by transforming growth factor beta. J Cell Physiol 2013;228:801-13.
42. Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem 2011;286:16218-28.
43. Kogan-Sakin I, Tabach Y, Buganim Y, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011;18:271-81.
44. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550-5.
45. Coradini D, Fornili M, Ambrogi F, et al. TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J Biomed Biotechnol 2012;2012:254085.
46. Muller PA, Caswell PT, Doyle B, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009;139:1327-41.
47. Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013;32:3286-95.
48. Quante T, Otto B, Brazdova M, et al. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 2012;11:3290-303.
49. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
50. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005;65:5996-6000;discussion 21.
51. Tarin D. Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev 2012;31:21-39.
52. Chui MH. Insights into cancer metastasis from a clinicopathologic perspective: epithelial-mesenchymal transition is not a necessary step. Int J Cancer 2013;132:1487-95.
53. Yeung T, Georges PC, Flanagan LA, et al. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil Cytoskeleton 2005;60:24-34.
54. Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity - implications for chemoresistance. Cancer Lett 2013;351:56-62.
55. Tsai JH, Donaher JL, Murphy DA, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer cell 2012;22:725-36.
56. Ding S, Zhang W, Xu Z, et al. Induction of an EMT-like transformation and MET in vitro. J Transl Med 2013;11:164.